761 related articles for article (PubMed ID: 16328005)
1. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
3. High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.
Kunze E; Schlott T
Int J Mol Med; 2007 Oct; 20(4):557-63. PubMed ID: 17786288
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
5. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
9. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
10. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
11. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.
Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S
J Urol; 2005 May; 173(5):1767-71. PubMed ID: 15821584
[TBL] [Abstract][Full Text] [Related]
12. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
13. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
[TBL] [Abstract][Full Text] [Related]
14. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
16. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Ping SY; Shen KH; Yu DS
Mol Carcinog; 2013 Jul; 52(7):568-79. PubMed ID: 22392726
[TBL] [Abstract][Full Text] [Related]
18. Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder.
Xuan Y; Kim S; Lin Z
J Cancer Res Clin Oncol; 2011 Jan; 137(1):49-54. PubMed ID: 20217126
[TBL] [Abstract][Full Text] [Related]
19. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
20. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
